

Liraglutide Helps Reduce Body Weight, HbA_{1c}

BY MIRIAM E. TUCKER
Senior Writer

ROME — The investigational, once-daily, human glucagon-like peptide-1 analog, liraglutide, produced a 1.5 percentage point drop in hemoglobin A_{1c}, as well as significant drops in body weight and blood pressure, in a study of patients with type 2 diabetes who were also taking metformin and rosiglitazone.

The findings of this 26-week phase IIIA randomized, placebo-controlled trial of 533 patients were reported by Dr. Bernard Zinman at a press briefing held during the annual meeting of the European Association for the Study of Diabetes.

The LEAD (Liraglutide Efficacy and Action in Diabetes) 4 trial, sponsored by Novo-Nordisk, comprised 533 subjects with a mean age of 55 years, mean body mass index of 33.5 kg/m², and mean HbA_{1c} of

The proportions of patients taking liraglutide who achieved an HbA_{1c} of less than 7.0% were 58% of those on the 1.2-mg dose and 54% of those on the 1.8-mg dose.

8.3%. All had been previously treated with at least one oral glucose-lowering agent. Dosages were titrated up to 8 mg of rosiglitazone and 2,000 mg of metformin therapy. The patients were then randomized to liraglutide (either

1.2 mg or 1.8 mg) injected once daily, or to placebo, said Dr. Zinman, professor of medicine at the University of Toronto and director of the diabetes center at Mount Sinai Hospital, Toronto.

At 26 weeks, HbA_{1c} levels had dropped from baseline by a statistically significant 1.5 percentage points in both the 1.2-mg and 1.8-mg liraglutide groups, to 7.0% and 7.1%, respectively, compared with a drop of just 0.5 percentage point (to 7.9%) in the placebo group.

The proportions who achieved an HbA_{1c} of less than 7.0% were 58% of those on the 1.2-mg dose and 54% of those on the 1.8-mg dose, compared with just 28% of the placebo group.

More than a third of both groups (36% of those on the 1.2-mg dose and 37% of those on the 1.8-mg dose) achieved HbA_{1c} levels of 6.5% or less.

Fasting plasma glucose (FPG) levels also dropped significantly with both liraglutide doses (by 2.2 mmol/L with 1.2 mg and by 2.4 mmol/L with 1.8 mg) to final FPG levels of 7.7 mmol/L and 7.6 mmol/L, respectively. The FPG drop in the placebo subjects was just 0.4 mmol/L (to 9.5 mmol/L).

Body weight dropped by 1.02 kg with the 1.2-mg dose and by 2.02 kg with the 1.8-mg dose, both statistically significant changes.

Mean systolic blood pressure levels were reduced by 6.7 mm Hg with the 1.2-mg dose and by 5.6 mm Hg with the 1.8-mg dose, compared with just 1.1 mm Hg with placebo, which were also statistically significant differences.

No major hypoglycemic episodes were

reported during the study. Minor hypoglycemia (defined as less than 3.1 mmol/L), occurred in 9% of the 1.2-mg group, 8% of the 1.8-mg group, and 5% of the placebo group. The rate of 0.64 events per subject per year that was seen in the 1.8-mg group was statistically significant, compared with the 0.17 rate seen in the placebo group.

Nausea was the most common adverse event reported, occurring in 29% of the 1.2-mg group and 40% of the 1.8-mg group, compared with just 9% with placebo.


Nausea occurred early in the treatment regimen and returned to placebo levels after 16 weeks.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States, as well as a marketing authorization application to the European Medicines Agency for the approval of liraglutide for the treatment of type 2 diabetes. If approved, liraglutide would be the first human-derived GLP-1 analog.

Exenatide (Byetta), the GLP-1 mimetic currently on the market, is derived from the salivary gland of a lizard.

Novo-Nordisk has completed a head-to-head comparison study that compares liraglutide with exenatide, both combined with metformin and sulfonylurea. Those results will be presented this month at the Canadian Diabetes Association annual meeting in Quebec.

Dr. Zinman is a consultant for Novo Nordisk Inc. ■



45%

For patients with very high triglycerides (≥ 500 mg/dL)

LOVAZA

4 g/day significantly reduced very high triglycerides by 45%^{*†1,2}

The LDL-C value for patients receiving LOVAZA increased from a median baseline of 89 mg/dL to a median of 109 mg/dL, a median increase of 45%^{1,2}

*In 2 randomized, placebo-controlled, double-blind, parallel-group studies of adult patients with baseline TG levels between 500 and 2000 mg/dL. The median baseline TG value for the group taking LOVAZA was 816 mg/dL and 788 mg/dL for the placebo group.
†Placebo increased triglycerides by 6.7%.

- **LOVAZA is the only prescription omega-3 product**
- **LOVAZA is derived from a natural source**
- **LOVAZA demonstrates an excellent safety and tolerability profile²**
- **Dosing: 4 grams QD[‡]**

LOVAZA[®] (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce very high (≥ 500 mg/dL) triglyceride (TG) levels in adult patients.


Important Safety Information

- LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication. LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.
- TG, LDL-C and ALT levels should be monitored periodically during therapy with LOVAZA. In some patients, LOVAZA increased LDL-C and ALT levels (without a concurrent increase in AST). Therapy with LOVAZA should be withdrawn in patients who do not have an adequate response after 2 months of treatment.
- Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.
- The most common adverse events reported were eructation, infection, flu syndrome, and dyspepsia. Discontinuation of treatment due to adverse events was similar to placebo: 3.5% of patients treated with LOVAZA and 2.6% of patients treated with placebo.

[‡]Or 2 grams BID.
References: 1. Data on file, GlaxoSmithKline. 2. Prescribing Information for LOVAZA, GlaxoSmithKline.

Please see a brief summary of Prescribing Information on the following page.


VISIT OUR WEB SITE AT www.LOVAZA.com/hcp



GlaxoSmithKline

© 2008 The GlaxoSmithKline Group of Companies
All rights reserved. LVZ117R0 July 2008

Proven. Potent. Pure.[®]



LOVAZA[®]
omega-3-acid ethyl esters